Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enobia Pharma has reported positive preclinical data demonstrating that its enzyme replacement therapy for hypophosphatasia appears to heal bones that have already been severely weakened by the disease.
Subscribe to our email newsletter
Earlier preclinical data showed that enzyme replacement therapy with Enobia’s product ENB-0040, significantly increases survival and prevents bone hypomineralization associated with hypophosphatasia, a rare genetic bone disease.
In these studies, subcutaneous administration of ENB-0040 was shown to significantly improve survival and prevent skeletal and dental manifestations of the disease.
Isabelle Lemire, associate director of non-clinical studies at Enobia Pharma, said: “We are extremely pleased to see evidence that enzyme replacement therapy with ENB-0040 may help repair skeletal damage caused by hypophosphatasia, as well as prevent the onset of dangerous bone hypomineralization.
“We look forward to advancing our clinical studies and confirming these results in patients with this deadly disease who currently have no approved treatment options.”